动脉粥样硬化社区风险研究中黑人与白人参与者2型糖尿病发病的全表观基因组关联研究
该研究前瞻性随访2091名黑人和1029名白人无2型糖尿病个体,中位随访17年,用Cox回归进行全表观基因组关联分析,发现7个新CpG位点与2型糖尿病发病相关,并复制了多个已知位点;显著CpG位点可在传统危险因素和空腹血糖基础上小幅增加2型糖尿病变异解释度。
要点
- 在黑人成人中鉴定出MICOS10、ZNF2、JPH3和GPX6等新发2型糖尿病相关CpG位点。
- JPH3和GPX6位点在校正BMI后仍达全表观基因组显著,仅JPH3位点在校正空腹血糖后保留显著。
- 显著CpG位点在传统危险因素和空腹血糖基础上小幅增加2型糖尿病变异解释度。
核心结论
- 本研究通过个体CpG位点分析和DMR分析在未探索人群中改进了CpG位点和区域的发现。
- JPH3和GPX6位点可能独立于BMI与2型糖尿病发病相关。
- 除JPH3位点外,所有CpG位点可能是血糖升高的结果。
研究设计与样本
- 前瞻性随访来自动脉粥样硬化社区风险研究的2091名黑人和1029名白人无2型糖尿病个体,中位随访17年。
- 使用Cox回归进行血液甲基化水平与2型糖尿病发病的全表观基因组关联分析。
- 所有分析均校正批次效应、细胞类型比例和相关混杂因素。
主要发现
- 在全表观基因组阈值10-7下检测到7个新的糖尿病相关CpG位点。
- 黑人成人中鉴定出MICOS10(cg05380846: HR 0.89, p=8.4×10-12)、ZNF2(cg01585592: HR 0.88, p=1.6×10-9)、JPH3(cg16696007: HR 0.87, p=7.8×10-9)和GPX6(cg02793507: HR 0.85, p=2.7×10-8; cg00647063: HR 1.20, p=2.5×10-8)位点。
- 白人成人中鉴定出chr17q25(cg16865890: HR 0.8, p=6.9×10-8)位点,meta分析组中鉴定出chr11p15(cg13738793: HR 1.11, p=7.7×10-8)位点。
- 显著CpG位点在传统2型糖尿病危险因素和空腹血糖基础上小幅增加变异解释度:黑人成人26.2% vs 30.5%,白人成人36.9% vs 39.4%。
- DMR分析显示ADCY7(pBlack=1.8×10-4, pWhite=3.6×10-3, pAll=1.6×10-9)和TP63启动子区(pBlack=7.4×10-4, pWhite=3.9×10-3, pAll=1.4×10-5)在所有种族和族裔组中差异甲基化。
关键数值与推荐
- 全表观基因组显著性阈值:10-7。
- DMR分析采用Šidák校正显著性阈值5%。
- 复制了已知2型糖尿病相关CpG位点,包括TXNIP的cg19693031、CPT1A的cg00574958、PLCB2的cg16567056、SREBF1的cg11024682、VPS25的cg08857797和ABCG1的cg06500161,其中三个在黑人成人中于全表观基因组阈值下复制,所有位点效应方向一致。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: DNA methylation studies of incident type 2 diabetes in US populations are limited and to our knowledge none include individuals of African descent. We aimed to fill this gap by identifying methylation sites (CpG sites) and regions likely influencing the development of type 2 diabetes using data from Black and White individuals from the USA. METHODS: We prospectively followed 2091 Black and 1029 White individuals without type 2 diabetes from the Atherosclerosis Risk in Communities study over a median follow-up period of 17 years, and performed an epigenome-wide association analysis of blood-based methylation levels with incident type 2 diabetes using Cox regression. We assessed whether significant CpG sites were associated with incident type 2 diabetes independently of BMI or fasting glucose at baseline. We estimated variation in incident type 2 diabetes accounted for by the major non-genetic risk factors and the significant CpG sites. We also examined groups of methylation sites that were differentially methylated. We performed replication of previously discovered CpG sites associated with prevalent and/or incident type 2 diabetes. All analyses were adjusted for batch effects, cell-type proportions and relevant confounders. RESULTS: At an epigenome-wide threshold (10-7), we detected seven novel diabetes-associated CpG sites, of which the sites at MICOS10 (cg05380846: HR 0.89, p=8.4 × 10-12), ZNF2 (cg01585592: HR 0.88, p=1.6 × 10-9), JPH3 (cg16696007: HR 0.87, p=7.8 × 10-9) and GPX6 (cg02793507: HR 0.85, p=2.7 × 10-8; cg00647063: HR 1.20, p=2.5 × 10-8) were identified in Black adults; chr17q25 (cg16865890: HR 0.8, p=6.9 × 10-8) in White adults; and chr11p15 (cg13738793: HR 1.11, p=7.7 × 10-8) in the meta-analysed group. The JPH3 and GPX6 sites remained epigenome-wide significant on adjustment for BMI, while only the JPH3 site retained significance after adjusting for fasting glucose. We replicated known type 2 diabetes-associated CpG sites, including cg19693031 at TXNIP, cg00574958 at CPT1A, cg16567056 at PLCB2, cg11024682 at SREBF1, cg08857797 at VPS25 and cg06500161 at ABCG1, three of which were replicated in Black adults at the epigenome-wide threshold and all of which had directionally consistent effects. We observed a modest increase in type 2 diabetes variance explained by the significantly associated CpG sites over and above traditional type 2 diabetes risk factors and fasting glucose (26.2% vs 30.5% in Black adults; 36.9% vs 39.4% in White adults). At the Šidák-corrected significance threshold of 5%, our differentially methylated region (DMR) analyses revealed several clusters of significant CpG sites, including a DMR consisting of a previously discovered CpG site at ADCY7 (pBlack=1.8 × 10-4, pWhite=3.6 × 10-3, pAll=1.6 × 10-9) and a DMR consisting of the promoter region of TP63 (pBlack=7.4 × 10-4, pWhite=3.9 × 10-3, pAll=1.4 × 10-5), which were differentially methylated across all racial and ethnic groups. CONCLUSIONS/INTERPRETATION: This study illustrates improved discovery of CpG sites and regions by leveraging both individual CpG site analysis and DMR analyses in an unexplored population. Our findings include genes linked to diabetes in experimental studies (e.g. GPX6, JPH3 and TP63). The JPH3 and GPX6 sites were likely associated with incident type 2 diabetes independently of BMI. All the CpG sites except that at JPH3 were likely consequences of elevated glucose. Replication in African-descent individuals of CpG sites previously discovered mostly in individuals of European descent indicates that some of these methylation-type 2 diabetes associations are robust across racial and ethnic groups. This study is a first step towards understanding the influence of methylation on the incidence of type 2 diabetes and its disparity in two major racial and ethnic groups in the USA. It paves the way for future studies to investigate causal relationships between type 2 diabetes and the CpG sites and potentially elucidate molecular targets for intervention.
引用
- Venkataraghavan S, Pankow JS, Boerwinkle E, et al. Epigenome-wide association study of incident type 2 diabetes in Black and White participants from the Atherosclerosis Risk in Communities Study. Diabetologia. 2025. PMID: 39971753. doi:10.1007/s00125-024-06352-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。